Clinical trial
Study Evaluating The Safety, Efficacy & Pharmacokinetics Of…
NCT00494091 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00494091 |
|---|---|
| Title | Study Evaluating The Safety, Efficacy & Pharmacokinetics Of Temsirolimus(CCI-779) In Subjects With Advanced Renal Cell Carcinoma |
| Official title | Phase 2, Non Randomized, Open Label Study Of Temsirolimus (CCI-779) In Subjects With Advanced Renal Cell Carcinoma (RCC) |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Renal Cell Carcinoma |
| Intervention type | Drug |
| Interventions | Temsirolimus (CCI-779) |
| Enrollment | 82 |
| Start date | Feb 1, 2007 |
| Primary completion | May 1, 2011 |
| Completion | Mar 1, 2012 |
| First posted | Jun 29, 2007 |
| Last update posted | Mar 21, 2013 |
| Countries | China, Japan, South Korea |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: